AEHR vs. TRNS, CTKB, SENS, LAB, EYPT, ALNT, QTRX, QSI, FEIM, and MASS
Should you be buying Aehr Test Systems stock or one of its competitors? The main competitors of Aehr Test Systems include Transcat (TRNS), Cytek Biosciences (CTKB), Senseonics (SENS), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Quanterix (QTRX), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Aehr Test Systems vs.
Transcat (NASDAQ:TRNS) and Aehr Test Systems (NASDAQ:AEHR) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Aehr Test Systems has lower revenue, but higher earnings than Transcat. Aehr Test Systems is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Transcat has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Aehr Test Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.
In the previous week, Transcat had 3 more articles in the media than Aehr Test Systems. MarketBeat recorded 5 mentions for Transcat and 2 mentions for Aehr Test Systems. Aehr Test Systems' average media sentiment score of 0.99 beat Transcat's score of 0.01 indicating that Aehr Test Systems is being referred to more favorably in the news media.
98.3% of Transcat shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 2.3% of Transcat shares are owned by company insiders. Comparatively, 6.2% of Aehr Test Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Transcat currently has a consensus target price of $111.50, indicating a potential upside of 56.93%. Aehr Test Systems has a consensus target price of $25.00, indicating a potential upside of 176.85%. Given Aehr Test Systems' stronger consensus rating and higher probable upside, analysts plainly believe Aehr Test Systems is more favorable than Transcat.
Aehr Test Systems has a net margin of 43.41% compared to Transcat's net margin of 6.22%. Aehr Test Systems' return on equity of 21.09% beat Transcat's return on equity.
Transcat received 79 more outperform votes than Aehr Test Systems when rated by MarketBeat users. Likewise, 66.14% of users gave Transcat an outperform vote while only 58.15% of users gave Aehr Test Systems an outperform vote.
Summary
Aehr Test Systems beats Transcat on 10 of the 18 factors compared between the two stocks.
Get Aehr Test Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aehr Test Systems Competitors List
Related Companies and Tools
This page (NASDAQ:AEHR) was last updated on 3/26/2025 by MarketBeat.com Staff
